HLB HLB Inc. Loading...

Loading chart...
Top Calls
Feed
Sources✓
YouTube✓
Twitter✓
Reddit✓
Substack✓
Insider✓
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
11:02
Jul 10
Lee Kwon-hee CEO, Economist 3PRO TV (삼프로TV)
Avoid HLB and Pepron biotech disasters
HLB faces habitual FDA rejection due to manufacturing concerns, and Pepron's CEO remarks shattered the key Lilly partnership thesis. Both stocks carry binary event risk and are not in major ETFs, so they are isolated but extremely dangerous. Avoid entirely.
HLB
HIGH
08:12
Jul 10
Lee Kwon-hee CEO, Economist 3PRO TV (삼프로TV)
Avoid HLB and Peptron biotech stocks.
HLB suffers from habitual FDA rejections driven by manufacturing facility issues; its lead drug is a licensed Chinese molecule, and no Korean company has ever independently secured FDA new drug approval. Peptron crashed after its CEO revealed it is not developing the key monthly tirzepatide obesity drug with Eli Lilly, destroying the main investment thesis. Both stocks carry severe downside risk and should be avoided.
HLB 1ST
HIGH

About HLB Analyst Coverage

Buzzberg tracks HLB (HLB Inc.) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 2 total trade ideas tracked. Past 7 days: 2 watch. Latest voices: Lee Kwon-hee.